Alchemab Therapeutics: Harnessing Natural Human Resilience for Drug Discovery

Alchemab Therapeutics is redefining antibody discovery by studying what goes right in health rather than what goes wrong in disease. The London-based biopharmaceutical company focuses on individuals who demonstrate remarkable resistance to severe conditions despite genetic predispositions that should make them vulnerable.

Company Overview & Recent Milestones

Founded in 2019 and headquartered in London with laboratories in Cambridge, Alchemab Therapeutics has developed a unique "resilience-first" approach to drug discovery. The company achieved a significant milestone in September 2025 by initiating a Phase 1 clinical trial of ATLX-1282, its lead candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Concurrent with the trial launch, Alchemab secured a $32 million Series A extension, bringing total Series A investment to $114 million.

The Science Behind Resilience-Based Discovery

Traditional drug development begins with understanding disease mechanisms in affected patients. Alchemab recognized that millions of people carry genetic risk factors for serious diseases yet never develop them. These "resilient" individuals possess naturally occurring protective mechanisms within their immune systems.

By studying protective antibodies from resilient populations, Alchemab identifies therapeutic targets that conventional disease-focused research might overlook. This approach leverages solutions that evolution has already validated—protective responses proven effective in human biology.

The DataCube: AI-Powered Platform

Alchemab's proprietary AI-enabled platform, "The DataCube," analyzes over 6,000 highly curated patient samples containing more than 350 million unique B cell sequences from over 30 global collaborators. The platform functions like a search engine for the immune system, using advanced machine learning to:

• Identify novel therapeutic targets through protective antibody screening
• Predict clinical efficacy using algorithmic modeling
• Accelerate discovery timelines compared to traditional methods
• Optimize candidate selection for development success

Strategic Partnerships with Eli Lilly

Alchemab has established two significant collaborations with Eli Lilly and Company:

• ATLX-1282 Licensing Agreement (May 2025): A landmark deal worth up to $415 million for Alchemab's first-in-class neurodegenerative candidate. Under this agreement, Alchemab conducts Phase 1 trials while Lilly leads subsequent development and commercialization.
• Discovery Collaboration (January 2025): A separate research partnership to discover, develop, and commercialize up to five additional therapeutic candidates for neurodegenerative diseases.

These partnerships validate Alchemab's platform while providing resources for clinical advancement in areas of significant unmet medical need.

Pipeline & Programs

ATLX-1282 emerged from studying individuals with genetic mutations typically associated with frontotemporal dementia who remained healthy into old age. Starting from this protective antibody sequence, Alchemab identified a novel target demonstrated to play important roles in neuroprotection across multiple neurodegenerative conditions.

ATLX-2847 represents Alchemab's wholly-owned muscle atrophy program targeting the prostaglandin pathway. The recent financing will advance this first-in-class candidate toward clinical development.

Additional programs span immunology, metabolic disorders, and oncology, all derived from the company's resilience-based discovery approach.

Leadership

Jane Osbourn, OBE, FMedSci, PhD serves as co-founder and CEO, bringing extensive experience from her previous role as Executive Vice President of R&D at MedImmune. Under her leadership, Alchemab has successfully established strategic partnerships, secured substantial funding, and advanced its lead program into clinical development.

Market Position & Competitive Advantages

Alchemab's approach provides several key differentiators in the competitive antibody therapeutics landscape:

• Novel Target Discovery: Identifies therapeutic targets through protective mechanisms that disease-focused competitors may overlook
• Clinically Validated Approach: Derives antibodies from naturally occurring protective responses already proven in human biology
• AI-Enhanced Efficiency: Accelerates screening and optimization compared to traditional laboratory-based methods
• Broad Application Potential: Platform applicability spans multiple therapeutic areas beyond neurodegenerative diseases

Future Outlook

With ATLX-1282 now in Phase 1 clinical trials and strong financial backing, Alchemab is positioned to validate its resilience-based drug discovery hypothesis. The company's success will ultimately depend on translating promising preclinical findings into safe and effective therapies for patients.

Alchemab's approach represents a fundamental shift in how biotechnology companies can approach therapeutic development—by studying human resilience rather than human disease, the company has created a differentiated platform to address conditions that have long resisted conventional therapeutic approaches.

‍